Technical Analysis for IDXG - Interpace Diagnostics Group, Inc.

Grade Last Price % Change Price Change
grade F 0.7717 11.84% 0.08
IDXG closed unchanged on Monday, April 22, 2019, on 88 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical IDXG trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 11.84%
New 52 Week Low Weakness 11.84%
Lower Bollinger Band Touch Weakness 11.84%
Oversold Stochastic Weakness 11.84%
Lower Bollinger Band Touch Weakness 11.84%
Oversold Stochastic Weakness 11.84%
New 52 Week Closing Low Bearish 11.84%
New 52 Week Low Weakness 11.84%
Below Lower BB Weakness 11.84%
Lower Bollinger Band Touch Weakness 11.84%

Older signals for IDXG ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, diagnostics, and healthcare companies in the United States. It operates in two segments, Commercial Services and Interpace Diagnostics. The Commercial Services segment offers outsourced sales teams that target healthcare providers, providing a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. This segment offers a range of personal and non-personal promotional options for the commercialization of their products throughout the product lifecycles, from development through maturity. It also provides other promotional services, including clinical educator, teledetailing, and full product commercialization services. This segment's services include product distribution, personal and non-personal product detailing, full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The Interpace Diagnostics segment focuses on developing and commercializing molecular diagnostic tests for physicians and patients with diagnostic options for detecting genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. This segment offers PancraGen, a diagnostic test designed for determining risk of malignancy in pancreatic cysts; and ThyGenX, a next-generation sequencing test designed to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules. It also has three diagnostic tests in late stage development that are designed to detect genetic alterations that are associated with gastrointestinal cancers; and one diagnostic test in late stage development that is designed to detect genetic alterations that are associated with endocrine cancers. PDI, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Biotechnology Cancer Healthcare Life Sciences Biology Supply Chain Management Healthcare Providers Medical Genetics Diagnostic Tests Qiagen
Is IDXG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.78
52 Week Low 0.67
Average Volume 270,644
200-Day Moving Average 1.0916
50-Day Moving Average 0.8774
20-Day Moving Average 0.7702
10-Day Moving Average 0.728
Average True Range 0.04
ADX 39.4
+DI 6.153
-DI 26.0032
Chandelier Exit (Long, 3 ATRs ) 0.7925
Chandelier Exit (Short, 3 ATRs ) 0.79
Upper Bollinger Band 0.8658
Lower Bollinger Band 0.6746
Percent B (%b) 0.08
BandWidth 24.824721
MACD Line -0.0536
MACD Signal Line -0.0489
MACD Histogram -0.0047
Fundamentals Value
Market Cap 15.29 Million
Num Shares 22.2 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -0.59
Price-to-Sales 2.01
Price-to-Book 0.69
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.74
Resistance 3 (R3) 0.73 0.72 0.73
Resistance 2 (R2) 0.72 0.71 0.72 0.72
Resistance 1 (R1) 0.70 0.70 0.70 0.71 0.72
Pivot Point 0.69 0.69 0.68 0.69 0.69
Support 1 (S1) 0.67 0.68 0.67 0.68 0.66
Support 2 (S2) 0.66 0.67 0.66 0.66
Support 3 (S3) 0.64 0.66 0.65
Support 4 (S4) 0.65